论文部分内容阅读
目的:观察益气清肝方联合拉米夫定治疗乙型肝炎肝硬化的疗效。方法:将58例患者随机分为2组,治疗组30例以益气清肝方联合拉米夫定治疗,对照组28例单用拉米夫定治疗,疗程52周。观察2组肝功能[谷丙转氨酶(ALT)、血清总胆红素(TBi)l、血清白蛋白(Alb)]、HBV DNA、Child-Pugh积分及乙肝两对半的变化。结果:治疗组患者HBV DNA阴转率高于对照组,2组比较,差异有显著性意义(P<0.05);2组HBeAg/HBeAb血清转换率、HBV DNA-YMDD变异率比较,差异无显著性意义(P>0.05)。2组患者治疗后ALT、TBil、Alb均较治疗前改善,差异均有显著性意义(P<0.05);治疗后治疗组ALT、TBil与对照组比较,差异均有显著性意义(P<0.05)。2组患者治疗后Child-Pugh积分均较治疗前改善,差异均有显著性意义(P<0.05)。结论:益气清肝方联合拉米夫定治疗乙型肝炎肝硬化疗效确切。
Objective: To observe the therapeutic effect of Yiqi Qinggan Decoction combined with lamivudine on hepatitis B cirrhosis. Methods: Fifty-eight patients were randomly divided into two groups. The treatment group was treated with Yiqi Qinggan Decoction combined with lamivudine, while the control group with lamivudine alone. 28 cases were treated with lamivudine for 52 weeks. The changes of liver function (ALT, TBi, Alb), HBV DNA, Child-Pugh score and hepatitis B two-and-a-half were observed in the two groups. Results: The negative rate of HBV DNA in the treatment group was higher than that of the control group, there was significant difference between the two groups (P <0.05). There was no significant difference in the mutation rate of HBeAg / HBeAb and the mutation rate of HBV DNA-YMDD between the two groups Sexual significance (P> 0.05). After treatment, ALT, TBil and Alb in both groups were significantly improved compared with those before treatment (P <0.05); after treatment, ALT and TBil in the treatment group were significantly different from those in the control group (P <0.05 ). Child-Pugh scores in both groups were significantly improved after treatment compared with before treatment (P <0.05). Conclusion: Yiqi Qinggan decoction combined with lamivudine treatment of hepatitis B cirrhosis is effective.